Frequently Asked Questions about PTC Therapeutics, Inc. (PTCT)

Name: PTC Therapeutics, Inc. (PTCT) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does PTC Therapeutics, Inc. (PTCT) do?

Accepted Answer

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinica...

Question 2

Is PTC Therapeutics, Inc. (PTCT) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of PTCT reveals an Altman Z-Score of 1.77 and a Piotroski F-Score of 6/9. These metrics, combined with its 5-year revenue trend ($1.73B most recent), help investors decide if PTCT fits their risk profile.

Question 3

What is the current P/E ratio for PTCT?

Accepted Answer

As of the latest trading session, PTC Therapeutics, Inc. (PTCT) has a trailing P/E ratio of 8.22.

Question 4

Who is the CEO of PTC Therapeutics, Inc.?

Accepted Answer

The current Chief Executive Officer of PTC Therapeutics, Inc. is Matthew Klein.

Question 5

What was PTCT's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, PTC Therapeutics, Inc. reported annual revenues of $1.73B (2025), $0.81B (2024), $0.94B (2023), $0.70B (2022), $0.54B (2021) respectively.

Question 6

Does PTCT pay a dividend?

Accepted Answer

PTC Therapeutics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does PTCT have?

Accepted Answer

In its latest reporting period, PTC Therapeutics, Inc. generated $0.70B in Free Cash Flow against a total debt load of $0.49B.

Question 8

What is the Price-to-Book (P/B) ratio of PTC Therapeutics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for PTC Therapeutics, Inc. (PTCT) is currently -27.32.

Question 9

What is the Price-to-Sales (P/S) ratio of PTCT?

Accepted Answer

Based on trailing twelve-month data, PTC Therapeutics, Inc. (PTCT) trades at a Price-to-Sales (P/S) ratio of 3.32.

Question 10

What is PTC Therapeutics, Inc.'s Return on Equity (ROE)?

Accepted Answer

PTC Therapeutics, Inc. (PTCT) has a Return on Equity (ROE) of -362.44%, representing its profitability relative to shareholder equity.

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	711.2M	0	-8.9M	702.3M	702.3M
2024-12	-107.7M	74.6M	-74.2M	-181.9M	-256.6M
2023-12	-158.4M	131.2M	-120.6M	-279M	-410.2M
2022-12	-356.7M	110.3M	-152.5M	-509.1M	-619.4M
2021-12	-251.3M	103.5M	-85.3M	-336.7M	-440.2M

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	711.2M	0	-8.9M	702.3M	702.3M
2024-12	-107.7M	74.6M	-74.2M	-181.9M	-256.6M
2023-12	-158.4M	131.2M	-120.6M	-279M	-410.2M
2022-12	-356.7M	110.3M	-152.5M	-509.1M	-619.4M
2021-12	-251.3M	103.5M	-85.3M	-336.7M	-440.2M